STOCK TITAN
  1. Home
  2. News
  3. MRTX

Mirati Therapeutics, Inc. - $MRTX STOCK NEWS

Welcome to our dedicated page for Mirati Therapeutics news (Ticker: $MRTX), a resource for investors and traders seeking the latest updates and insights on Mirati Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mirati Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mirati Therapeutics's position in the market.

News
Mirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer
Rhea-AI Summary
Mirati Therapeutics presents two-year follow-up data on adagrasib in NSCLC patients with KRASG12C mutation at the 2023 World Conference on Lung Cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
conferences clinical trial
-
News
Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Rhea-AI Summary
Mirati Therapeutics, Inc. (Nasdaq: MRTX) has closed an underwritten public offering, generating approximately $345.0 million in gross proceeds. The offering included 11,288,336 shares of common stock at $27.80 per share and pre-funded warrants to purchase 1,121,736 shares of common stock at $27.799 per pre-funded warrant. Goldman Sachs & Co. LLC was the book-running manager for the offering, and Leerink Partners LLC acted as the financial advisor. The securities were offered pursuant to a shelf registration statement filed with the SEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
-
News
Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 Inhibition
Rhea-AI Summary
Mirati Therapeutics, Inc. announced the publication of preclinical and initial clinical data for MRTX1719, a PRMT5/MTA inhibitor, in Cancer Discovery. The data demonstrate that MRTX1719 may represent a promising targeted therapy for cancer patients with MTAP deletion, with marked anti-tumor activity observed in preclinical studies. In the Phase 1/2 trial, six confirmed objective responses were observed, and MRTX1719 was well-tolerated with no dose-limiting toxicities observed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.95%
Tags
clinical trial
News
Mirati Therapeutics Announces Pricing of Upsized Public Offering
Rhea-AI Summary
Mirati Therapeutics, Inc. announces pricing of public offering, expected to raise $300.0 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.09%
Tags
offering
-
News
Mirati Therapeutics Announces Proposed Public Offering
Rhea-AI Summary
Mirati Therapeutics announces $250.0 million public offering of common stock and pre-funded warrants. Underwriters may purchase additional $37.5 million of shares. Offering subject to market conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.09%
Tags
offering
-
News
Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
Rhea-AI Summary
MRTX - Mirati Therapeutics, Inc. Announces Phase 3 Study, MRTX1719 Clinical Data, and CEO Transition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.09%
Tags
earnings
News
Mirati Therapeutics Announces Departure of Chief Executive Officer David Meek
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.09%
Tags
none
-
News
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Mirati Therapeutics, Inc.® (NASDAQ: MRTX) granted equity awards to a new employee as part of an equity inducement plan, including options to purchase 5,189 shares of common stock and 3,067 restricted stock units (RSUs). The options have an exercise price of $30.02 per share, with vesting schedules outlined for both the options and RSUs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
none
-
News
Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
conferences earnings
News
Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.39%
Tags
none
Stock MRTX logo
Mirati Therapeutics, Inc.

Nasdaq:MRTX

MRTX Rankings

N/A Ranked by Market Cap
#3193 Ranked by Stock Gains
N/A Ranked by Dividends

MRTX Stock Data

4.12B
38.91M
1.72%
117.76%
6.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About MRTX

mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.